Myeloid CE / CME

Home About Contact Add Activities Provider Login

	Ace the Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment? Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. American Academy of CME
	Ace the Case: Older Adult with Therapy-Related AML Knowledge of the key management issues for patients with AML is critical Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. American Academy of CME
	Ace the Case: Supporting Older Adults with AML Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications. American Academy of CME

Ace the Case: Newly Diagnosed AML: Can Molecular Markers Direct Treatment?

Knowledge of the key management issues for patients with AML is critical. Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications.
American Academy of CME

Ace the Case: Older Adult with Therapy-Related AML

Knowledge of the key management issues for patients with AML is critical Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications.
American Academy of CME

Ace the Case: Supporting Older Adults with AML

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map